Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System.

María Elena Cabrera Camila PeñaPilar LeonVivianne LoisHernán RojasValeska VegaAlvaro PizarroSusana CalderonChristine RojasAugusto AspillagaM Luisa GonzalezMarvila IntriagoBernardita RojasCecilia HalesJacqueline OlivaMónica RomeroMarisa CapurroJorge J Castillo

Published in: JCO global oncology (2022)

Rituximab improved the survival of patients with DLBCL diagnosed and treated in Chile. The benefit was sustained over time, with curative rates of > 50%. This intervention shows that the inclusion of this biological drug justified the expenses incurred by the Ministry of Health in the National Lymphoma Protocols in Chile.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
healthcare
mental health
randomized controlled trial
public health
adverse drug
health information
emergency department
prognostic factors
risk assessment
climate change
health promotion